Industries > Pharma > Asthma & COPD Therapies Market Report 2020-2030

Asthma & COPD Therapies Market Report 2020-2030

Forecasts by Treatment (Bronchodilator Monotherapy (Anticholinergics (Spiriva, Atrovent, Eklira, Others), SABA (Ventolin, ProAir, Proventil, Xoponex, Others), LABA (Foradil, Arcapta/Onbrez, Brovana, Serevent, Others)), (Anti-Inflammatory Drugs (Corticosteroids (Pulmicort, Flixotide, QVAR, Asmanex, Others), Anti-Leukotrienes (Singulair, Others), Monoclonal Antibodies (Xolair, Cinqair, Nucala, Benralizumab, Lebrikizumab, Dupilumab)), Others, (Combination Drugs (Advair, Symbicort, Combivent, Dulera, Relvar/Breo, Others)), by Route of Administration (Oral, Inhaled, Others), by Point of Sale/Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Others), Geography (North America, Europe, Asia Pacific, Rest of the World) PLUS COVID-19 Impact Scenarios and Profiles of Leading Asthma & COPD Companies

PUBLISHED: 10 August 2020
PAGES: 318
PRODUCT CODE: PHA0783
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA0783 Categories: , Tag:

COPD and Asthma Therapeutics – our new study reveals trends, R&D progress, and predicted revenues
Where is the COPD and asthma therapeutics market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there.

Discover how to stay ahead
Our 310+ page report provides 370+ tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing COPD and Asthma Therapeutics Market. See how to exploit the opportunities.

Forecasts to 2030 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2030, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect your industry. Access this report today.

To access the data contained in this document please email contactus@visiongain.com

CTA

Discover sales predictions for the world market and submarkets

By Treatment:

• Bronchodilator Monotherapy
– Anticholinergics: Spiriva, Atrovent, Eklira, Others
– SABA: Ventolin, ProAir, Proventil, Xoponex, Others
– LABA: Foradil, Arcapta/Onbrez, Brovana, Serevent, Others

• Anti-Inflammatory Drugs
– Corticosteroids: Pulmicort, Flixotide, QVAR, Asmanex, Others
– Anti-Leukotrienes: Singulair, Others
– Monoclonal Antibodies: Xolair, Cinqair, Nucala, Benralizumab, Lebrikizumab, Dupilumab
– Others

• Combination Drugs
– Advair
– Symbicort
– Combivent
– Dulera
– Relvar/Breo
– Others

By Route of Administration:
• Oral
• Inhaled
• Others

By Point of Sale/Distribution Channel:
• Retail pharmacies
• Hospital pharmacies
• Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 4 regional and 10 leading national markets:

By Region:

• North America
– U.S.
– Canada

• Europe
– Germany
– France
– UK
– Italy
– Spain
– Rest of Europe

• Asia Pacific
– China
– Japan
– India
– Rest of APAC

• Rest of the World

Asthma & COPD Therapies Market Report 2020-2030

The report also includes profiles and for some of the leading companies in the COPD and asthma therapeutics Market, with a focus on this segment of these companies’ operations.

There will be growth in both established and in developing countries. Our analyses show that the both developed and developing markets, U.S., Germany, UK and Japan, China in particular, will continue to achieve high revenue growth to 2030.

Leading companies and the potential for market growth
Overall world revenue for COPD and Asthma Therapeutics Market will surpass US$ xx million in 2020, our work calculates. We predict strong revenue growth through to 2030.

Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How the COPD and Asthma Therapeutics Market report helps you
In summary, our 310+ page report provides you with the following knowledge:

• Revenue forecasts to 2030 for COPD and Asthma Therapeutics Market, with forecasts for Treatment, Route of Administration, and Distribution Channel, each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues

• Revenue forecasts to 2030 for 4 regional and 10 key national markets – See forecasts for the COPD and Asthma Therapeutics market in North America, Europe, Asia-Pacific and Rest of the World. Also forecasted is the market in the US, Canada, Germany, France, UK, Italy, Spain, China, India, and Japan.

• Prospects for established firms and those seeking to enter the market– including company profiles for 12 of the major companies involved in the COPD and Asthma Therapeutics Market. Some of the company’s profiles in this report include AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Teva, Merck, F. Hoffmann-La Roche AG.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions.

Visiongain’s study is for everybody needing commercial analyses for the COPD and Asthma Therapeutics Market and leading companies. You will find data, trends and predictions.

To access the data contained in this document please email contactus@visiongain.com

Buy our report today Asthma & COPD Therapies Market Report 2020-2030: Forecasts by Treatment (Bronchodilator Monotherapy (Anticholinergics (Spiriva, Atrovent, Eklira, Others), SABA (Ventolin, ProAir, Proventil, Xoponex, Others), LABA (Foradil, Arcapta/Onbrez, Brovana, Serevent, Others)), (Anti-Inflammatory Drugs (Corticosteroids (Pulmicort, Flixotide, QVAR, Asmanex, Others), Anti-Leukotrienes (Singulair, Others), Monoclonal Antibodies (Xolair, Cinqair, Nucala, Benralizumab, Lebrikizumab, Dupilumab)), Others, (Combination Drugs (Advair, Symbicort, Combivent, Dulera, Relvar/Breo, Others)), by Route of Administration (Oral, Inhaled, Others), by Point of Sale/Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Others), Geography (North America, Europe, Asia Pacific, Rest of the World) PLUS COVID-19 Impact Scenarios and Profiles of Leading Asthma & COPD Companies. Avoid missing out by staying informed – order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Asthma & COPD Therapies Market Report 2020-2030


Download sample pages

Complete the form below to download your free sample pages for Asthma & COPD Therapies Market Report 2020-2030


Latest Pharma news

Visiongain Publishes Healthcare Cold Chain Logistics Market Report 2020-2030

. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.

16 September 2020

READ

Visiongain Publishes Vaccines Sales Market Report 2020-2030

Visiongain forecasts a continuing growth in global market, submarket and product sales as human vaccines drive pharmaceutical business sales. New key players and technological progress will enter the industry, leading to an increase in the market size of the world market for human vaccines in general.

14 September 2020

READ

Visiongain Publishes Ophthalmic Ultrasound Systems Market Report 2020-2030

The global ophthalmic ultrasound systems market is driven by factors such as the increasing prevalence of ocular disorders and diseases, adoption of novel ophthalmic technologies, rising focus on research & development, and growing health awareness amongst the population.

09 September 2020

READ

Visiongain Publishes Drug Discovery Outsourcing Market Report 2020-2030

The current COVID-19 pandemic is anticipated to have a minor impact on the overall outsourcing business outlook for global drug discovery. Also, significant growth during the COVID-19 pandemic is expected to be seen in the outsourcing of drugs and medicines needed to treat COVID-19 infections.

07 September 2020

READ

Categories

Category